at pharmatimes.com
The European Commission has charged Lundbeck and eight other pharmaceutical companies (including Merck KGaA, Ranbaxy and Alpharma) regarding alleged 'pay-for-delay' tactics relating to the Danish drugmaker's antidepressant Celexa.
The Commission has issued a 'statement of objections' to Lundbeck regarding agreements concluded with four generic competitors concerning Celexa (citalopram). It is claimed that the generics companies "abstained from entering the market" and received "direct payments as well as other forms such as purchase of generic citalopram stock for destruction or guaranteed profits in a distribution agreement".
No comments:
Post a Comment